Form 4: IO Biotech Director Acquires Stock Options

Director David V. Smith acquired 45,642 stock options in IO Biotech, Inc. on June 6, 2024.

Summary

• David V. Smith, a director of IO Biotech, Inc., acquired 45,642 stock options on June 6, 2024.
• The options have an exercise price of $1.25.
• The options vest on June 6, 2025, contingent upon continued service and are subject to full acceleration upon a change of control.
• The options expire on June 6, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider buying can be seen as positive, this is an option grant, which is part of standard compensation.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders, like directors, transact in their company's securities. This filing indicates a transaction by a director of IO Biotech.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates